Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CB 03 10

Next Previous
Drug Profile

CB 03 10

Alternative Names: CB-03-10; Cortexolone 17α-valerate-21-propionate; Cortexolone derivative - Cosmo Pharmaceuticals

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Class Antineoplastics; Esters; Pregnenediones; Propionates; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase II Diverticulitis; Hepatic encephalopathy; Malabsorption syndromes
  • No development reported Solid tumours

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 14 Jun 2022 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03863145)
  • 24 May 2022 Phase-II clinical trials in Diverticulitis in Ireland (PO) (Cosmo Pharmaceuticals pipeline, May 2022).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top